华南预防医学 ›› 2023, Vol. 49 ›› Issue (7): 858-862.doi: 10.12183/j.scjpm.2023.0858

• 论著 • 上一篇    下一篇

凝血酶联合生长抑素对消化道出血患者炎性因子、凝血及纤溶效果影响

吴海棠1, 杨维忠2, 劳方1   

  1. 1.临高县中医院,海南 临高 571800;
    2.海南医学院第二附属医院
  • 收稿日期:2023-03-01 出版日期:2023-07-20 发布日期:2023-10-12
  • 作者简介:吴海棠(1973—),男,大学专科,主治医师,主要从事消化系统疾病诊疗工作
  • 基金资助:
    海南省卫生健康行业科研项目(20A200330)

Effects of thrombin combined with somatostatin on inflammatory factors, coagulation, and fibrinolysis in patients with gastrointestinal bleeding

WU Haitang1, YANG Weizhong2, LAO Fang1   

  1. 1. Lingao County Traditional Chinese Medicine Hospital, Lingao 571800, China;
    2. The Second Affiliated Hospital of Hainan Medical College
  • Received:2023-03-01 Online:2023-07-20 Published:2023-10-12

摘要: 目的 探讨凝血酶联合生长抑素对消化道出血患者炎性因子、凝血及纤溶效果影响。方法 以接受凝血酶联合生长抑素治疗的患者作为观察组,以未接受凝血酶治疗的患者为对照组,对2组治疗后的止血疗效、治疗前后炎性因子、凝血指标、纤溶指标水平、治疗过程中的不良反应发生情况进行比较。结果 治疗后2组血清TNF-α、IL-6、CRP、TT、PT、APTT、FIB水平以及D-D水平均有所下降,且观察组上述各指标水平均显著低于对照组(P<0.05或P<0.01),观察组上述指标治疗前后差值均大于对照组(均P<0.01)。治疗后2组血清IL-2、APTT、t-PA以及PAI水平有所上升,且观察组上述指标水平均显著高于对照组(均P<0.01),观察组上述指标治疗前后差值均小于对照组(P<0.05或P<0.01)。观察组不良反应发生率显著低于对照组(P<0.05)。结论 对于消化道出血患者采用凝血酶联合生长抑素联合治疗的疗效更佳,可以有效抑制炎性因子水平、改善凝血功能和血管纤溶状态,且安全性较高。

关键词: 凝血酶, 生长抑素, 消化道出血, 炎性因子, 凝血, 纤溶

Abstract: Objective To investigate the effects of thrombin combined with somatostatin on inflammatory factors, coagulation, and fibrinolysis in patients with gastrointestinal bleeding. Methods Patients who received thrombin combined with somatostatin treatment were selected as the observation group, and patients who did not receive thrombin treatment were selected as the control group. The hemostatic effect after treatment, the levels of inflammatory factors, coagulation index and fibrinolysis index before and after treatment, and the occurrence of adverse reactions during treatment were compared between the two groups. Results After treatment, the levels of serum TNF-α, IL-6, CRP, TT, PT, FIB, and D-D in the two groups decreased, and the levels of the above indexes in the observation group were significantly lower than those in the control group (P<0.05 or P<0.01). The differences of the above indexes before and after treatment in the observation group were greater than those in the control group (all P<0.01). After treatment, the levels of serum IL-2, APTT, t-PA,APTT and PAI in the two groups increased, and the levels of the above indexes in the observation group were significantly higher than those in the control group (all P<0.01). The differences of the above indexes before and after treatment in the observation group were lower than those in the control group (P<0.05 or P<0.01). The incidence of adverse reactions in the observation group was significantly lower than that in the control group (P<0.05). Conclusion For patients with gastrointestinal bleeding, the combination of thrombin and somatostatin has better efficacy, which can effectively control the level of inflammatory factors, improve coagulation function and vascular fibrinolysis state, and has high safety.

Key words: Thrombin, Somatostatin, Gastrointestinal bleeding, Inflammatory factor, Coagulation, Fibrinolysis

中图分类号: 

  • R575.2